These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 7153881)

  • 1. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.
    Sheiner LB; Beal SL
    J Pharm Sci; 1982 Dec; 71(12):1344-8. PubMed ID: 7153881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics.
    Kelman AW; Whiting B; Bryson SM
    Br J Clin Pharmacol; 1982 Aug; 14(2):247-56. PubMed ID: 7104175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A method for estimating within-individual variability in clearance and in volume of distribution from standard bioavailability studies.
    Upton RA; Thiercelin JF; Moore JK; Riegelman S
    J Pharmacokinet Biopharm; 1982 Apr; 10(2):135-46. PubMed ID: 7120044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A package of computer programs designed to simulate pharmacokinetic monitoring of drug therapy.
    Sullivan TJ; Wunderley DJ
    Comput Programs Biomed; 1980 Dec; 12(2-3):85-95. PubMed ID: 7249607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs. pharmacokinetic studies.
    el Desoky E; Meinshausen J; Bühl K; Engel G; Harings-Kaim A; Drewelow B; Klotz U
    Ther Drug Monit; 1993 Aug; 15(4):281-8. PubMed ID: 8236362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian approaches in pharmacokinetic decision making.
    Schumacher GE; Barr JT
    Clin Pharm; 1984; 3(5):525-30. PubMed ID: 6488735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.
    Sheiner LB; Beal SL
    J Pharmacokinet Biopharm; 1980 Dec; 8(6):553-71. PubMed ID: 7229908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?
    Brooks E; Tett SE; Isbel NM; Staatz CE
    Clin Pharmacokinet; 2016 Nov; 55(11):1295-1335. PubMed ID: 27138787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in strategies for dosage regimen individualization.
    Marouani H; Woloch C; Benay S; Frances N; Iliadis A
    Curr Top Med Chem; 2012; 12(15):1669-77. PubMed ID: 22978335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.
    Sheiner LB; Beal SL
    J Pharmacokinet Biopharm; 1983 Jun; 11(3):303-19. PubMed ID: 6644555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Bayesian estimation of pharmacokinetic parameters.
    Tsuchiwata S; Mihara K; Yafune A; Ogata H
    Ther Drug Monit; 2005 Feb; 27(1):18-24. PubMed ID: 15665741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hierarchical Bayesian approach to population pharmacokinetic modelling.
    Smith A; Wakefield J
    Int J Biomed Comput; 1994 Jun; 36(1-2):35-42. PubMed ID: 7927858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian forecasting in paediatric populations.
    Fernández de Gatta MM; García MJ; Lanao JM; Domínguez-Gil A
    Clin Pharmacokinet; 1996 Nov; 31(5):325-30. PubMed ID: 9118582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A calculator program for clinical application of the Bayesian method of predicting plasma drug levels.
    Ruffo S; Messori A; Grasela TH; Longo G; Donati-Cori G; Matucci M; Morfini M; Tendi E
    Comput Programs Biomed; 1985; 19(2-3):167-77. PubMed ID: 3928243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian hierarchical modeling of receptor occupancy in PET trials.
    Vandenhende F; Renard D; Nie Y; Kumar A; Miller J; Tauscher J; Witcher J; Zhou Y; Wong DF
    J Biopharm Stat; 2008; 18(2):256-72. PubMed ID: 18327720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control.
    Jelliffe RW; Schumitzky A; Van Guilder M; Liu M; Hu L; Maire P; Gomis P; Barbaut X; Tahani B
    Ther Drug Monit; 1993 Oct; 15(5):380-93. PubMed ID: 8249044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimates of the population pharmacokinetic parameters and performance of Bayesian feedback: a sensitivity analysis.
    Vozeh S; Steiner C
    J Pharmacokinet Biopharm; 1987 Oct; 15(5):511-28. PubMed ID: 3694495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of Bayesian microcomputer predictions of theophylline concentrations in newborn infants.
    Murphy MG; Peck CC; Merenstein GB; Rodden D
    Ther Drug Monit; 1990 Jan; 12(1):47-53. PubMed ID: 2305421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Bayesian methods for multivariate bioequivalence measures.
    Molina de Souza R; Achcar JA; Martinez EZ
    J Biopharm Stat; 2009; 19(1):42-66. PubMed ID: 19127466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An efficient control strategy for dosage regimens.
    Hu C; Lovejoy WS; Shafer SL
    J Pharmacokinet Biopharm; 1994 Feb; 22(1):73-94. PubMed ID: 8027950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.